{"schema_version":"secwatch.filing_event.v1","accession":"0001367644-23-000166","form_type":"8-K","ticker":"EBS","cik":"0001367644","company_name":"Emergent BioSolutions Inc.","filed_at":"2023-10-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.766274+00:00","generated_at":"2026-06-10T06:19:00.426089+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Emergent BioSolutions appoints DeGolyer and Fowler to board, adopts inducement plan","bullets":["Donald DeGolyer and Neal Fowler appointed Class III directors effective Oct 1, 2023; terms expire at 2024 annual meeting.","Both are independent; DeGolyer on Compensation Committee, Fowler on Audit and Finance Committee.","Each receives initial RSU grant valued at $375,000, vesting in three equal annual installments.","Board adopted Inducement Plan reserving 5 million shares for equity grants to new hires."],"urls":{"canonical":"https://secwatch.observer/filing/0001367644-23-000166","json":"https://secwatch.observer/filing/0001367644-23-000166.json","markdown":"https://secwatch.observer/filing/0001367644-23-000166.md","text":"https://secwatch.observer/filing/0001367644-23-000166.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1367644/000136764423000166/0001367644-23-000166-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1367644/000136764423000166/ebs-20230928.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T06:19:00.426089+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1241bbec61","claim":"Neal Fowler was appointed as Class III Director at Emergent BioSolutions Inc..","evidence_excerpt":"On September 28, 2023, the Board of Directors (the “Board”) of Emergent BioSolutions Inc. (the “Company”) appointed Donald DeGolyer and Neal Fowler as Class III directors effective October 1, 2023","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1367644/000136764423000166/0001367644-23-000166-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class III Director"}],"fact_type":"executive_change"},{"claim_id":"e784fafe21","claim":"Donald DeGolyer was appointed as Class III Director at Emergent BioSolutions Inc..","evidence_excerpt":"On September 28, 2023, the Board of Directors (the “Board”) of Emergent BioSolutions Inc. (the “Company”) appointed Donald DeGolyer and Neal Fowler as Class III directors effective October 1, 2023","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1367644/000136764423000166/0001367644-23-000166-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class III Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}